Objective:To improve the clinical recognition of hereditary fibrinogen deficiency.Methods:The diagnosis and treatment process of a patient with acute promyelocytic leukemia (APL) complicated with hereditary fibrinogen deficiency who was admitted to the second Affiliated Hospital of Anhui Medical University in December 2018 was retrospectively analyzed, and the relevant literature was reviewed.Results:The patient was initially diagnosed as APL, and the complete remission was obtained after dual-induction therapy of all-trans retinoid acid and arsenous acid. During the first consolidation treatment, repeated reviews of fibrinogen fluctuated between 1.0-1.5g/L, and further improving the fibrinogen gene sequencing to diagnose APL combined with hereditary fibrinogen deficiency.Conclusion:For APL patients in remission who have decreased fibrinogen for many times and patients with hereditary fibrinogen deficiency who have significantly decreased fibrinogen in a short period, bone marrow biopsy and genetic testing should be further conducted to determine the pathogenesis.

At present ICU transition management in China is still in the exploration stage, and the existing research results are difficult to be promoted in the clinic, and the management plan lacks unified and feasible standards. This paper introduces the concept and model of ICU transition management, and provides an overview of the current situation of ICU transition management for patients transferred out of ICU, adverse outcomes for patients transferred out of ICU, and the content of ICU transition management for patients transferred out of ICU, aiming to provide a reference for the formation of a unified and standardized ICU transition management scheme.